Zealand Pharma news

ZEAL · Nasdaq Copenhagen · DKK

kr 258.30−2.75%−kr 7.30

Close · October 6, 2026

Latest news

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) (opens in a new tab)
GlobeNewswire · Oct 5, 2026
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts (opens in a new tab)
Oct 1, 2026
Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial (opens in a new tab)
MT Newswires · Oct 1, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes (opens in a new tab)
GlobeNewswire · Oct 1, 2026
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 (opens in a new tab)
GlobeNewswire · Sep 30, 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology (opens in a new tab)
GlobeNewswire · Sep 29, 2026
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) (opens in a new tab)
GlobeNewswire · Sep 28, 2026
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity (opens in a new tab)
GlobeNewswire · Sep 22, 2026
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) (opens in a new tab)
GlobeNewswire · Sep 21, 2026
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome (opens in a new tab)
GlobeNewswire · Sep 18, 2026
Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License (opens in a new tab)
Simply Wall St. · Sep 18, 2026
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes (opens in a new tab)
Sep 15, 2026
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (opens in a new tab)
GlobeNewswire · Sep 14, 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants (opens in a new tab)
GlobeNewswire · Sep 10, 2026
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference (opens in a new tab)
Sep 9, 2026
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) (opens in a new tab)
Sep 7, 2026
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (opens in a new tab)
Sep 2, 2026
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough (opens in a new tab)
Sep 1, 2026
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (opens in a new tab)
Aug 31, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (opens in a new tab)
Aug 28, 2026